This evening we watched Royalty Pharma rise 3.0% to a price of $53.25 per share. The Large-Cap Pharmaceutical company is now trading -10.13% below its average target price of $59.25. Analysts have set target prices ranging from $46.0 to $66.0 per share for Royalty Pharma, and have given the stock an average rating of buy.
Royalty Pharma's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 3.1%. The stock's short ratio is 4.65. The company's insiders own 7.14% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Another number to watch is the company's rate of institutional share ownership, which now stands at 85.6%. In conclusion, we believe there is positive market sentiment regarding Royalty Pharma.
Institutions Invested in Royalty Pharma
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-12-31 | Morgan Stanley | 12% | 55,274,069 | $2,943,344,174 |
| 2025-12-31 | Capital International Investors | 7% | 31,104,309 | $1,656,304,454 |
| 2025-12-31 | FMR, LLC | 6% | 26,272,308 | $1,399,000,401 |
| 2025-12-31 | Blackrock Inc. | 6% | 26,188,692 | $1,394,547,849 |
| 2026-03-31 | BAILLIE GIFFORD & CO | 4% | 16,155,677 | $860,289,800 |
| 2025-12-31 | Adage Capital Partners GP L.L.C. | 3% | 11,740,594 | $625,186,630 |
| 2026-03-31 | Swedbank AB | 3% | 11,586,693 | $616,991,402 |
| 2025-12-31 | State Street Corporation | 2% | 10,649,641 | $567,093,383 |
| 2025-12-31 | Geode Capital Management, LLC | 2% | 7,719,843 | $411,081,639 |
| 2025-12-31 | Caledonia (Private) Investments Pty Ltd | 2% | 7,377,038 | $392,827,273 |
